Sean Maduck Sells 20,000 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $73.99, for a total transaction of $1,479,800.00. Following the completion of the sale, the insider directly owned 7,904 shares in the company, valued at approximately $584,816.96. This represents a 71.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sean Maduck also recently made the following trade(s):

• On Wednesday, October 1st, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $85.06, for a total value of $1,701,200.00.
• On Tuesday, September 2nd, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.49, for a total value of $1,409,800.00.

Corcept Therapeutics Trading Down 4.7%

Shares of CORT stock opened at $73.06 on Friday. The stock has a market cap of $7.70 billion, a price-to-earnings ratio of 64.66 and a beta of 0.43. The stock has a 50-day moving average of $76.74 and a 200-day moving average of $73.40. Corcept Therapeutics Incorporated has a 1-year low of $49.00 and a 1-year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 20.10% and a net margin of 18.51%.The company had revenue of $207.64 million during the quarter, compared to analyst estimates of $223.78 million. During the same period in the prior year, the firm earned $0.41 earnings per share. Corcept Therapeutics’s revenue was up 13.8% compared to the same quarter last year. Corcept Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Institutional Trading of Corcept Therapeutics

Several large investors have recently made changes to their positions in the company. Huntington National Bank increased its position in Corcept Therapeutics by 54.0% in the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 168 shares in the last quarter. Focus Partners Wealth grew its stake in Corcept Therapeutics by 0.5% in the first quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company’s stock valued at $3,797,000 after acquiring an additional 170 shares during the period. Campbell Newman Asset Management Inc. grew its stake in Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock valued at $2,953,000 after acquiring an additional 170 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Corcept Therapeutics by 1.8% during the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 180 shares in the last quarter. Finally, Brooklyn Investment Group raised its position in shares of Corcept Therapeutics by 99.5% during the first quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 186 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CORT has been the subject of several recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 1st. Piper Sandler dropped their price objective on Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating on the stock in a research note on Friday, August 1st. HC Wainwright restated a “buy” rating and set a $145.00 target price on shares of Corcept Therapeutics in a research report on Monday, October 20th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $140.00 target price on shares of Corcept Therapeutics in a research note on Thursday, September 25th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Corcept Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $135.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.